Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.700 -0.100 (-3.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
JAGX Stock Alert: What Is Going on With Jaguar Health Today?
JAGX stock is rallying on Wednesday after a rough year thanks to news that Oasis Capital has taken a 10% stake in Jaguar Health. 
Via InvestorPlace
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians,... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock moved upwards by 69.5% to $4.44 during Wednesday's pre-market session. The market value of their outstanding shares is at $25.2... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! Let's get this party started with a dive into the biggest pre-market stock movers to watch for Wednesday! 
Via InvestorPlace
15 Stocks Moving in Wednesday's Pre-Market Session
Gainers Kidpik Corp. (NASDAQ: PIK) rose 34.4% to $8.13 in pre-market trading after jumping more than 27% on Tuesday. Kidpik, last month, posted a Q3 loss of $0.22 per share.... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) stock... 
Via Benzinga
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV... 
Via Benzinga
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs
The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BioRestorative Therapies (NASDAQ:BRTX... 
Via Benzinga
JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher
Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment. 
Via InvestorPlace
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4... 
Via Benzinga
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics... 
From Jaguar Health, Inc.
Via AccessWire
European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health SAN... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aptinyx (NASDAQ:APTX) shares rose... 
Via Benzinga
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2" SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Looking Into Jaguar Health's Return On Capital Employed
According to data from Benzinga Pro, during Q3, Jaguar Health's (NASDAQ:JAGX) reported sales totaled $630.00 thousand. Despite a 17.71% increase in earnings, the company posted a... 
Via Benzinga
Jaguar Health: Q3 Earnings Insights
Jaguar Health (NASDAQ:JAGX) reported its Q3 earnings results on Wednesday, November 17, 2021 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Jaguar Health Reports 2021 Third Quarter Financial Results
Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health's Earnings Outlook
Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Wednesday, 2021-11-17. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Earnings Scheduled For November 17, 2021
Companies Reporting Before The Bell • ZIM Integrated Shipping (NYSE:ZIM) is projected to report quarterly earnings at $9.25 per share on revenue of $2.77 billion.... 
Via Benzinga
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.